Aldeyra Q1 net loss $15.6M; PDUFA dates set; clinical readouts in Q2 2023

Aldeyra Therapeutics, Inc.

2023-Q1 EPS reported $0.27

Net loss $15.6M ($0.27 loss per share) vs $16.8M ($0.29) in Q1 2022.
Cash and equivalents $165.0M; projected runway into H2 2024.
PDUFA dates: ADX-2191 (June 21, 2023) for vitreoretinal lymphoma; reproxalap (Nov 23, 2023) for dry eye.
Top-line Q2 2023: Phase 2 ADX-2191 (retinitis pigmentosa), Phase 2 ADX-629 (chronic cough), Phase 3 INVIGORATE-2 (allergic conjunctivitis).
Aldeyra will discontinue quarterly earnings conference calls, citing shift to clinical/regulatory updates.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aldeyra Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 4, 2023, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) issued a press release (the “Press Release”) regarding its financial results for the quarter ended March 31, 2023 and recent corporate highlights.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Aldeyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-23-000722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.